This systematic review and meta-analysis compared the efficacy of dienogest (DNG) and gonadotropin-releasing hormone (GnRH) agonists in the management of endometriosis-related symptoms following surgical intervention, their related adverse effects, and …
Adenomyosis and endometriosis are hormone-dependent benign gynecological disorders with overlapping features suggesting that they may share a common origin despite being considered distinct entities. This study compares the expression of …
Adenomyosis occurs when endometrial glands and stroma grow within the uterine myometrium. As a clinically significant disease, adenomyosis causes substantial pelvic pain and heavy menstrual bleeding. It remains understudied due …
Adolescent-onset endometriosis is increasingly recognized as a distinct clinical challenge. It often requires years to achieve a diagnosis, leading to prolonged physical and psychological distress and significantly impairing quality of …
Lipedema is a chronic, progressive disorder marked by the abnormal accumulation of subcutaneous adipose tissue, predominantly in the lower body and almost exclusively affecting women. In recent years, the off-label …
Although per- and polyfluoroalkyl substances (PFAS) exposure has been linked to endometriosis, this association remains controversial, and the underlying mechanisms are unclear. This study aimed to investigate this relationship and …
To identify risk factors that predict the persistence of noncyclical pelvic pain in patients with endometriosis despite receiving hormone therapy.
Objectives: To evaluate the impact of hormonal therapy on the evolution of painful symptoms in premenopausal women with adenomyosis, with or without concomitant endometriosis, over an 18-month follow-up period. This …
Gonadotropin-releasing hormone pulsatility is under the influence of hypothalamic neuropeptides, especially neurons expressing kisspeptin, neurokinin B, and dynorphin. These hypothalamic cells are called KNDy neurons. By integrating hormonal and environmental …
Elagolix, Linzagolix, and Relugolix, as oral gonadotropin-releasing hormone antagonists, have emerged as promising treatments for endometriosis-associated pain.